REGENXBIO to Report 2025 Financials, Highlight Pipeline Progress
Event summary
- REGENXBIO will host a conference call on March 5, 2026, to discuss Q4 and full-year 2025 financial results.
- The call will also cover operational highlights, including progress in its late-stage gene therapy pipeline.
- Key therapies discussed will include RGX-202 for Duchenne, RGX-121 and RGX-111 for MPS II and MPS I (partnered with Nippon Shinyaku), and ABBV-RGX-314 for wet AMD and diabetic retinopathy (partnered with AbbVie).
- A replay of the webcast will be available on the company's investor website approximately two hours after the call's conclusion.
The big picture
REGENXBIO's upcoming earnings call comes at a critical juncture for the gene therapy sector, where late-stage pipeline progress and financial performance are key indicators of long-term viability. The company's partnerships with Nippon Shinyaku and AbbVie underscore the strategic importance of collaborative efforts in advancing innovative treatments for rare and retinal diseases. Investors will be closely watching how these factors play out in the context of broader biotech market trends.
What we're watching
- Pipeline Execution
- How REGENXBIO's progress with RGX-202, RGX-121, RGX-111, and ABBV-RGX-314 will impact its market positioning.
- Financial Performance
- Whether the company's financial results reflect sustained growth or indicate potential challenges ahead.
- Partnership Dynamics
- The pace at which collaborations with Nippon Shinyaku and AbbVie will drive commercial success.
Related topics